During the last session, CymaBay Therapeutics Inc. (NASDAQ:CBAY)’s traded shares were 1.1 million, with the beta value of the company hitting 0.29. At the end of the trading day, the stock’s price was $8.55, reflecting an intraday gain of 0.59% or $0.05. The 52-week high for the CBAY share is $11.22, that puts it down -31.23 from that peak though still a striking 78.83% gain since the share price plummeted to a 52-week low of $1.81. The company’s market capitalization is $826.61M, and the average intraday trading volume over the past 10 days was 1.59 million shares, and the average trade volume was 1.64 million shares over the past three months.
CymaBay Therapeutics Inc. (CBAY) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. CBAY has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.19.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
CymaBay Therapeutics Inc. (NASDAQ:CBAY) trade information
CymaBay Therapeutics Inc. (CBAY) registered a 0.59% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.59% in intraday trading to $8.55 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -5.52%, and it has moved by -15.76% in 30 days. Based on these gigs, the overall price performance for the year is 347.64%. The short interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) is 11.07 million shares and it means that shorts have 6.69 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.20, which implies an increase of 39.79% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $19.00 respectively. As a result, CBAY is trading at a discount of -122.22% off the target high and 6.43% off the low.
CymaBay Therapeutics Inc. (CBAY) estimates and forecasts
Statistics show that CymaBay Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. CymaBay Therapeutics Inc. (CBAY) shares have gone up 161.47% during the last six months, with a year-to-date growth rate more than the industry average at 16.53% against 6.20. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 38.70% this quarter and then drop -3.60% in the quarter after that.
Revenue for the current quarter is expected to be $14.63 million as predicted by 7 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.90%. While earnings are projected to return 4.70% in 2023.
CBAY Dividends
CymaBay Therapeutics Inc. is due to release its next quarterly earnings between May 10 and May 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
CymaBay Therapeutics Inc. (NASDAQ:CBAY)’s Major holders
CymaBay Therapeutics Inc. insiders own 0.31% of total outstanding shares while institutional holders control 74.39%, with the float percentage being 74.62%. Avoro Capital Advisors LLC is the largest shareholder of the company, while 162 institutions own stock in it. As of Mar 30, 2023, the company held over 10.3 million shares (or 10.56% of all shares), a total value of $89.82 million in shares.
The next largest institutional holding, with 7.5 million shares, is of Janus Henderson Group PLC’s that is approximately 7.69% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $65.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of CymaBay Therapeutics Inc. (CBAY) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.4 million shares. This amounts to just over 2.46 percent of the company’s overall shares, with a $15.04 million market value. The same data shows that the other fund manager holds slightly less at 1.12 million, or about 1.15% of the stock, which is worth about $7.03 million.
